ERBB2 and mucinous neoplasm: In our study, HER2 3+ scores had the highest incidence among mucinous tumors (18.8%), followed by endometrioid (9.1%) and clear cell (9.1%) types, each demonstrating a two-fold elevation compared to high-grade serous tumors (4.6%).